The HPV Testing and Pap Test Market size in Europe is estimated to be worth USD 1.38 billion by 2026 and USD 1.03 billion in 2021, growing at a CAGR of 6.10% during the forecast period. It captures 25% of the global market.
The rising number of patients diagnosed with cervical cancer, the growing elderly population, and greater awareness about cervical cancer screening programs contribute to the European HPV testing and pap test market growth. Doctors use Pap testing to confirm cervical cancer in women or to investigate alterations in cells that might lead to cervical cancer in the future. Because of the disease's high incidence and death rate, there is a great need for novel and reliable early detection and therapy screening. Furthermore, market development is expected to be aided by innovative testing methods and services that would increase screening rates. Therefore, one of the key factors expected to drive Europe's HPV testing and Pap test market over the forecast period is rising demand for technologically advanced diagnostic procedures for screening cervical and vaginal cancers.
Because of the HPV test's excellent sensitivity, it can be used to extend screening intervals and enhance screening coverage in high-risk populations. Alternative approaches such as HPV testing have emerged due to the failure of cytology-based screening programs in this region. The rising need for improved cancer diagnostics, as well as recent advances in cancer diagnosis and therapy, novel specific antigen discovery, and insights linked to cancer's genetic foundation, have all contributed to the market's rise. The growing elderly population will also add gasoline to this industry, as they will increase demand for additional cancer assays and tests, resulting in the future market growth in Europe. For women aged 25 and older, one HPV test has just been approved for use as primary cervical cancer screening, followed by a Pap test for women with specific findings. Many additional tests are also being developed to enhance the assessment of HPV-positive women. As a result of the rising demand for Pap, HPV, and other cancer screening tests, the market has grown.
The European HPV Testing and Pap Test market is projected to be restrained by regulatory clearances for screening techniques, an uncertain reimbursement environment over the forecast period. The authorized tests on the market are for detecting cervical cancer in women. They are ineffective in males for detecting HPV-related malignancies or genital warts. Because of the restricted product availability, the market's growth has been constrained to a single gender, resulting in modest development during the forecast period.
Changes in regulatory guidelines for cervical cancer screening and the HPV vaccine are key challenges to the European HPV testing and Pap test market growth.
This research report on the Europe HPV Testing and Pap Test Market has been segmented and sub-segmented into the following categories:
By Test Type:
By Application:
By End-users:
By Country:
Regionally, Europe is the second-largest market in terms of market share in the global market. The UK is the leading market in this region. Government leaders, members of parliament, and activists should be aware that the much larger scale of this public health crisis in the EU's east requires special attention. The high levels of awareness of the condition and the testing methods and related advantages among the people of these areas were major drivers in the market's rise in these regions. Cervical cancer, often known as uterine cancer, is becoming a major public health concern in several European nations. Cervical cancer is particularly prevalent in the new member nations. Romania and Lithuania now have the highest yearly death rates, while Finland has the lowest.
KEY MARKET PLAYERS:
A few of the prominent companies operating in the European HPV Testing and PAP Test Market profiled in this report are Abbott Laboratories, Qiagen N.V., Roche Diagnostics, Hologic, Inc., Becton, Dickinson and Company, Quest Diagnostics, Onco Health Corporation, Seegene, Inc., Femasys Inc., and Arbor Vita Corporation.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 HPV Testing
5.1.3 Follow-Up HPV Testing
5.1.4 Co-Testing
5.1.5 Primary HPV Testing
5.1.6 PAP Test
5.1.7 Y-o-Y Growth Analysis, By Type
5.1.8 Market Attractiveness Analysis, By Type
5.1.9 Market Share Analysis, By Type
5.2 Application
5.2.1 Introduction
5.2.2 Cervical Cancer Screening
5.2.3 Vaginal Cancer Screening
5.2.4 Y-o-Y Growth Analysis, By Application
5.2.5 Market Attractiveness Analysis, By Application
5.2.6 Market Share Analysis, By Application
5.3 End User
5.3.1 Introduction
5.3.2 Laboratories
5.3.3 Hospitals
5.3.4 Physicians’ Offices and Clinics
5.3.5 Y-o-Y Growth Analysis, By End User
5.3.6 Market Attractiveness Analysis, By End User
5.3.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Application
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Application
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Application
6.1.5.4 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Qiagen N.V.
8.3 Roche Diagnostics
8.4 Hologic, Inc.
8.5 Becton, Dickinson and Company
8.6 Quest Diagnostics
8.7 Onco Health Corporation
8.8 Seegene, Inc.
8.9 Femasys Inc.
8.10 Arbor Vita Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
